In a move aimed at effectively controlling the prices of certain prescription drugs, the Centers for Medicare & Medicaid Services (CMS) announced on Tuesday, August 29, 2023, the first set of ten drugs that will be liable to price negotiation with manufacturers under the newly applied Inflation Reduction Act of 2022 (IRA) Medicare Drug Price Negotiation Program (Price Negotiation Program).
The announcement by the CMS sets a precedent for future engagements with manufacturers in the prescription drug market, shifting focus towards a more balanced price control mechanism.
Though the specific drugs selected for the Price Negotiation Program haven’t been disclosed in this preliminary announcement, there’s keen anticipation within the industry about the impact of the new scheme. The goal of the Price Negotiation Program is to lessen the financial burden on American citizens who require constant medical care. The financial implications for the prescription drug industry, however, remain to be fully understood.
This move lies in the broader context of ongoing efforts by federal and state bodies to rein in escalating drug prices, which have been a point of concern for the public in recent years. The Inflation Reduction Act of 2022, under which this Price Negotiation Program fall, has been enacted with the same aim.
Keeping a strict watch on the developments, especially the response of drug manufacturers, will be critical for legal professionals working in the field. As the conversation around drug pricing continues to evolve, there will likely be a significant impact on future legislation and legal action in this arena in the coming years.